Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs
Shots:
- Biohaven & Merus have entered into a research collaboration & license agreement to co-develop bispecific ADCs using the former’s ADC conjugation & payload platform plus Merus’ Biclonics tech platform
- As per the terms, Biohaven will develop preclinical ADCs for 3 Merus’ BsAbs (2 developed via Biclonics & 1 in preclinical) & each is eligible for advancement through mutual agreement, with shared development costs & commercialization
- Merus will get an upfront & license fee on the nomination of 1st ADC program plus will handle the BsAb development cost while Biohaven will fund the ADC generation
Ref: Merus| Image: Merus & Biohaven
Related News:- Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
